Jaime SotoPaula SotoAndrea AjataDaniela RiveroCarmelo LuqueCarlos TintayaJonathan Berman2026-03-222026-03-22201810.4269/ajtmh.18-0183https://doi.org/10.4269/ajtmh.18-0183https://andeanlibrary.org/handle/123456789/45728Citaciones: 16Bolivian cutaneous leishmaniasis due to <i>Leishmania braziliensis</i> was treated with the combination of miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 μg/mm² lesion area on days 1, 3, and 5). Ninety-two per cent of 50 patients cured. Comparison to historic controls at our site suggests that the efficacy of the two drugs was additive. Adverse effects and cost were also additive. This combination may be attractive when a prime consideration is efficacy (e.g., in rescue therapy), avoidance of parenteral therapy, or the desire to treat locally and also provide systemic protection against parasite dissemination.enMiltefosinePentamidineLeishmaniasisLeishmania braziliensisLeishmaniaAdverse effectCutaneous leishmaniasisMedicineLesionDermatologyarticle